Akums Drugs & Pharmaceuticals Ltd Stock Price Today (NSE: AKUMS)

Akums Drugs & Pharmaceuticals Ltd

531.25+6.60 (+1.26%)
Market Open

Fundamental Score

...

Akums Drugs & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Akums Drugs & Pharmaceuticals Ltd share price today is 531.25, up +1.26% on NSE/BSE as of 19 June 2026. Akums Drugs & Pharmaceuticals Ltd (AKUMS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 6.70K (Cr). The 52-week high for AKUMS share price is 597.00 and the 52-week low is 409.30. At a P/E ratio of 21.76x, AKUMS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 17.19% and a debt-to-equity ratio of 0.03.

Akums Drugs & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
567.00
Low
500.05
Volume
2.7L
Change
+0.69%

Akums Drugs & Pharmaceuticals Ltd share price chart: 0.69% return over the past month. 52-week high ₹597.00, 52-week low ₹409.30.

Akums Drugs & Pharmaceuticals Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
520.95533.40517.00531.2588.38K (Cr)
524.50543.90523.20524.651.72L (Cr)
537.90543.00522.00524.5084.91K (Cr)
535.05548.50535.00535.252.18L (Cr)
521.60551.60521.60532.203.02L (Cr)
530.00531.85514.90521.001.19L (Cr)
523.50525.45516.60520.052.22L (Cr)
516.00527.40509.15521.352.21L (Cr)
516.00523.65510.35514.953.22L (Cr)
519.75530.90517.95519.803.01L (Cr)

Akums Drugs & Pharmaceuticals Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
524.50543.90517.00531.25+1.29%
550.00567.00500.05524.50-4.64%
473.90557.00473.90547.30+15.49%
472.00515.00456.55466.10-1.25%
445.00506.00424.20488.15+9.70%
453.40458.00409.30439.55-3.05%
425.95480.50414.00453.40+6.44%
463.95481.70411.40425.95-8.19%
441.50473.45437.00460.75+4.36%
456.00484.00438.05441.45-3.19%
520.00524.85452.20454.25-12.64%
588.50592.00511.70519.25-11.77%

AI Research Briefing

Powered by Gemini · 2026-04-17

CDMO play with EU optionality; execution is everything.

Research Confidence
6.0/10Moderate
OPERATOR-DRIVENConsolidation. 1M: -7.81%, 3M: -10.14%, 6M: -23.34%Fair. P/E of 21.76x vs. Industry P/E of 31.77x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Akums Drugs shows bullish momentum with positive daily moving averages. 84% increase from the previous close. ICICI Securities upgraded the stock to 'Hold' on April 10, 2026. FII holding increased to 1.38% in March 2026 from 1.14% in December 2025. Akums closed its trading window on April 1, 2026, in anticipation of FY26 results.

CORE STORY (THE REAL GAME)

Akums is being priced as a CDMO play, leveraging its manufacturing capabilities for regulated markets. The key is its ability to secure and execute long-term contracts with global pharma companies, shifting from generics to higher-margin formulations.

Why Now
  • Bullish technical indicators signal upward price momentum
  • FIIs increased stake in Q4 FY26
  • EU GMP certifications received, paving the way for regulated market access
Potential Catalysts
  • New CDMO contract wins
  • Successful commencement of European supplies in FY28
  • Faster-than-expected ramp-up of Zambia JV
Key Risks
  • Small-cap, inherent liquidity risk
  • Q2 PAT decline raises concerns about CDMO growth sustainability
  • Revenue concentration risk from reliance on large contracts
Institutional Activity

FII increased stake from 1.14% to 1.38% in Q4 FY26

Macro Context

Indian pharma sector shifting towards backward integration and innovation.

Order Book / Expansion

Akums has a ₹1,760 Cr contract with a European pharma company for oral liquid formulations, with commercial supply expected from 2027.

Cash Flow Quality

Profit converting to cash. Free Cash Flow 5Y: ₹132.48 Cr

3–6 Month Outlook

Focus on executing existing contracts and securing new ones in regulated markets. European expansion is key to margin expansion over the next 2-3 years.

Primary Thesis Risk

Failure to execute on EU expansion will decimate the multiple.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Good

Return on Equity (ROE)

17.19%

Profit generated per ₹1 of shareholder equity

Average

Return on Capital (ROCE)

16.20%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

5.62%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Akums Drugs & Pharmaceuticals Ltd Valuation Check

Excellent

Price to Earnings (P/E)

21.76x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

75.26%

% shares held by company founders/management

Poor

FII Holding

2.27%

% shares held by foreign institutional investors

Average

DII Holding

9.28%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-34.83%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-1.51%

Revenue growth vs same quarter last year

Good

Revenue Growth (5-Year CAGR)

11.27%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-42.93%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

48.93%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.03x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

6.61x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

132.48 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Akums Drugs & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of AKUMS across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Strong Return on Equity (17.19%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (16.20%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 21.76 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Profit Growth Track Record (48.93% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.03)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (6.61x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹132.48 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Profit Decline Concern (-34.83%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Weak Earnings Growth (-42.93% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Akums Drugs & Pharmaceuticals Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Akums Drugs & Pharmaceuticals Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
46.1/100
531
₹6697.10
21.8
Average
17.19%
Good
16.20%
Good
0.0
Excellent
48.93%
Excellent
11.27%
Good
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Akums Drugs & Pharmaceuticals Ltd PE Ratio History

Historical price-to-earnings ratio for AKUMS — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202522.60₹453.4020.1x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Akums Drugs & Pharmaceuticals Ltd Quarterly Performance

Latest quarterly metrics for AKUMS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-1.51%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-34.83%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

11.27%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

48.93%

Compounded annual net profit growth over 5 years

Akums Drugs & Pharmaceuticals Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for AKUMS — calculated from daily price history

44RSI 14
Neutral — RSI 44

Momentum is balanced — neither overbought nor oversold.

SMA 50
516
▲ Price above SMA 50 — Short-term bullish
SMA 200
470
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
256K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Akums Drugs & Pharmaceuticals Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Akums Drugs & Pharmaceuticals Ltd (AKUMS) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Akums Drugs & Pharmaceuticals Ltd

About AKUMS (Akums Drugs & Pharmaceuticals Ltd)

Akums Drugs & Pharmaceuticals Ltd. is a powerhouse within the Indian pharmaceutical landscape, standing as a comprehensive contract development and manufacturing organization (CDMO...). They function as a vital hub, orchestrating the production of a vast portfolio of pharmaceutical and healthcare solutions, spanning from essential medications to sophisticated formulations. The company's expertise extends across diverse therapeutic areas, catering to both acute and chronic conditions with unwavering commitment to quality and innovation. With a strong foothold in the domestic market, Akums also strategically projects its reach globally, solidifying its position as a reliable partner for pharmaceutical companies seeking manufacturing excellence. This unwavering dedication has positioned Akums as a significant contributor to the healthcare industry, enabling the provision of affordable and quality healthcare solutions for diverse demographics. Beyond conventional pharmaceuticals, Akums embraces a holistic approach to well-being, demonstrated by its involvement in the production of ayurvedic medicines, herbal remedies, and nutraceuticals. This reflects an awareness of the growing consumer demand for natural and alternative therapies, with production conducted under rigorous regulatory standards and quality controls. The company's comprehensive product range further incorporates toiletries, derma and cosmetic products, and food supplements, showcasing its diversification and commitment to addressing various aspects of health and personal care. Akums is dedicated to continuously refining its processes and technologies, ensuring the delivery of products that align with the evolving needs of the healthcare industry. Akums Drugs & Pharmaceuticals Ltd. operates a network of state-of-the-art manufacturing facilities adhering to stringent international quality standards, including certifications from WHO-GMP and other reputed regulatory bodies. This infrastructural strength enables the company to deliver a wide range of dosage forms, including tablets, capsules, liquids, injectables, and topical preparations. Moreover, the company offers a comprehensive suite of services encompassing formulation development, analytical testing, and stability studies, positioning it as a complete solution provider for pharmaceutical companies. By fostering collaborations and partnerships, Akums aims to drive advancements in healthcare, enabling access to quality and affordable medicines for populations worldwide.

Company Details

Symbol:AKUMS
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Sanjeev Jain
Co-Founder, MD & Whole Time Director
Mr. Sandeep Jain
Co Founder, MD & Director
Mr. Sumeet Sood
Chief Financial Officer

AKUMS Share Price: Frequently Asked Questions

What is the current share price of Akums Drugs & Pharmaceuticals Ltd?

Akums Drugs & Pharmaceuticals Ltd (AKUMS) trades at ₹531.25 on NSE and BSE. Market cap ₹6.70K (Cr). Educational data only.

What is the P/E ratio of Akums Drugs & Pharmaceuticals Ltd?

Akums Drugs & Pharmaceuticals Ltd has a P/E of 21.76x vs industry average 31.77x.

What is the Bull Run score for Akums Drugs & Pharmaceuticals Ltd?

Akums Drugs & Pharmaceuticals Ltd has a Bull Run score of 46.1/100 based on 25+ financial parameters.

Does Akums Drugs & Pharmaceuticals Ltd pay dividends?

Akums Drugs & Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Akums Drugs & Pharmaceuticals Ltd?

Akums Drugs & Pharmaceuticals Ltd has ROE of 17.19%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Akums Drugs & Pharmaceuticals Ltd?

Akums Drugs & Pharmaceuticals Ltd has debt-to-equity of 0.03.

Is Akums Drugs & Pharmaceuticals Ltd a good investment?

Bull Run gives Akums Drugs & Pharmaceuticals Ltd a score of 46.1/100. This is not investment advice — consult a SEBI-registered advisor.